LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Strona główna・Stock List・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Closed

SectorHealthcare

1.5 0.67

Buy Sell

Overview

Share price change

24h

Current

Min

1.47

Max

1.55

Key metrics
By Trading Economics
Income	-16M -13M
Sales	-15M 14M
Profit margin	-90.037
Employees	103
EBITDA	-16M -10M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+172.3% upside

Dividends
By Dow Jones
Next Earnings	5 mar 2026

Market Stats
By TradingEconomics
Market Cap	137M 631M
Previous open	0.83
Previous close	1.5

News Sentiment

By Acuity

50%

161 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

0.6863 / 0.72 Support & Resistance

Lexicon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 lut 2026, 23:07 UTC

Earnings

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 23:01 UTC

Earnings

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:59 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 lut 2026, 22:42 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 lut 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 lut 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 lut 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 lut 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24 lut 2026, 23:16 UTC

Earnings

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 lut 2026, 23:13 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 lut 2026, 23:12 UTC

Earnings

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 lut 2026, 23:08 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 lut 2026, 23:07 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 lut 2026, 22:52 UTC

Earnings

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 22:46 UTC

Earnings

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Warner Receives New Bid From Paramount -- 3rd Update

24 lut 2026, 22:29 UTC

Earnings

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 lut 2026, 22:28 UTC

Earnings

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 lut 2026, 22:25 UTC

Earnings

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 lut 2026, 22:24 UTC

Earnings

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 lut 2026, 22:23 UTC

Earnings

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 lut 2026, 22:22 UTC

Earnings

Woolworths Interim Dividend 45 Australian Cents/Share

24 lut 2026, 22:22 UTC

Earnings

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 lut 2026, 22:21 UTC

Earnings

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

172.3% upside

12 Months Forecast

Average 4.03 USD 172.3%

High 6 USD

Low 2.1 USD

Based on 3 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Lexicon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.6863 / 0.72Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

161 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.